Last Updated: November 19, 2026
Quick Summary
A compounded GLP-1 prescription must be written for a specific patient by a licensed prescriber who has evaluated that patient, with a documented clinical reason an FDA-approved product is unsuitable. The prescription must include patient and prescriber details, the drug strength, dose, quantity, date, and the prescriber’s signature, and the pharmacy must be licensed in the patient’s state.
- Compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality before reaching patients.
- Under Section 503A, the compounded drug must be made for a named patient based on a valid prescription.
- The prescriber’s file should document the diagnosis, why an approved product was not appropriate, and the follow-up plan.
- Shortage status can change eligibility, so confirm the FDA drug shortage database entry before filling each refill.
- Confirm the pharmacy’s state license and the prescriber’s license before starting any compounded GLP-1 medication.
Table of Contents
- What Compounded GLP-1 Medications Are and How They Differ From FDA-Approved Drugs
- Federal Compounding Rules Under Sections 503A and 503B
- Individual Patient Prescription and Clinical Evaluation Requirements
- Checklist: What a Valid Compounded GLP-1 Prescription Should Contain
- Checking Whether Compounded GLP-1 Is Still Permitted: Shortage Status and Ban Updates
- Safety Considerations for Compounded Semaglutide and Compounded B12 Blends
- Next Step: Confirming Eligibility and Verifying Your Prescriber and Pharmacy
- Frequently Asked Questions
What Compounded GLP-1 Medications Are and How They Differ From FDA-Approved Drugs
Compounded GLP-1 medications are custom-mixed versions of drugs like semaglutide and tirzepatide, prepared by a pharmacy for a specific patient. Unlike FDA-approved products, they are not reviewed by the U.S.
Compounding is meant for situations where a standard product does not fit a patient’s needs. A patient might need a different dose, a different form, or an ingredient left out because of an allergy. FDA guidance on compounded drugs explains that compounding is a legal exception, not a routine substitute for approved medicines.
Here is the core distinction:
- FDA-approved drugs have passed clinical trials and manufacturing review.
- Compounded drugs are made to order and carry no FDA approval of the final product.
- Compounded drugs must still meet federal conditions to qualify for legal exemptions.
Compounded GLP-1 medications are not intended as long-term replacements for FDA-approved options when those options are available, except in limited circumstances. GoodRx overview of compounded GLP-1 medications describes compounding as a limited pathway rather than a routine alternative.
Federal Compounding Rules Under Sections 503A and 503B
Two sections of the Federal Food, Drug, and Cosmetic Act create the main legal pathways for compounding: Section 503A and Section 503B. They are not interchangeable, and the pathway a product falls under changes who may make it, how it must be made, and what prescription or order is required. FDA clarification on compounding exemptions under sections 503A and 503B is the primary reference for the conditions attached to each.
Section 503A: patient-specific compounding by traditional pharmacies
Section 503A applies to licensed traditional pharmacies that compound for identified individual patients. The core conditions are:
- The drug is compounded for a specific patient based on a valid prescription from a licensed prescriber who has evaluated that patient.
- The compounding pharmacy is licensed in the state where it operates and complies with applicable state law.
- The pharmacy does not compound drugs that are essentially copies of a commercially available FDA-approved product, except in limited circumstances such as a documented clinically significant difference for that patient.
A 503A pharmacy cannot compound in anticipation of receiving prescriptions for an unnamed patient. Stockpiling a compounded GLP-1 product before a prescription arrives does not fit the 503A model.
Section 503B: outsourcing facilities compounding in larger quantities
Section 503B applies to entities that register with FDA as outsourcing facilities. These facilities:
- Register with FDA and are subject to inspection.
- Must comply with current good manufacturing practice requirements.
- May compound without a patient-specific prescription, but only for drugs that appear on FDA’s 503B bulks list or otherwise meet the statutory conditions.
An outsourcing facility is not a traditional pharmacy, and a 503A pharmacy cannot simply relabel itself as a 503B facility without registering and meeting the manufacturing standards.
A practical decision tree for 503A versus 503B eligibility
Use this sequence to determine which pathway a compounded GLP-1 product is likely to fall under. It is a screening tool, not a legal opinion; a licensed pharmacist or attorney should confirm the final answer.
- Is the product made for a named patient after a prescription? If yes, the 503A pathway is the starting point. If the product is made in advance for general supply, move to step 4.
- Does the pharmacy hold a license in the patient’s state and in the state where it operates? If not, the 503A exemption is not available for that patient.
- Is the compounded drug essentially a copy of an FDA-approved GLP-1 product? If yes, confirm a documented clinically significant difference for that patient before relying on 503A. If no documented difference exists, the 503A pathway is at risk.
- Is the entity registered with FDA as a 503B outsourcing facility? If not, it cannot compound in advance for general supply under 503B.
- Is the bulk drug substance eligible for 503B use? If the substance is not on the 503B bulks list and does not otherwise meet the statutory conditions, the 503B pathway is not available.
- Does the facility follow current good manufacturing practice and meet reporting obligations? If not, the 503B exemption does not apply.
Watch out: a pharmacy that markets itself as “503A compliant” while shipping to patients in states where it is not licensed is a common failure point, and the prescription may not be legally fillable.
What this means for a compounded GLP-1 prescription
For most individual patients, the 503A pathway is the relevant one, which is why the prescription and clinical evaluation requirements in the next section matter so much. The 503B pathway matters more when a product is made in larger quantities and shipped across state lines without a patient-specific prescription. Neither pathway makes a compounded drug the legal or clinical equivalent of an FDA-approved product, and neither removes the need to check shortage status and state rules.
Individual Patient Prescription and Clinical Evaluation Requirements
For a 503A pharmacy, the prescription is the starting point. A patient-specific prescription must come from a licensed prescriber who has evaluated that patient.
A valid clinical evaluation should show a medical need for the compounded version. That usually means the approved product is unsuitable for this patient.
Prescribers should document their reasoning clearly. The file should show:
- The patient’s diagnosis and relevant history
- Why an FDA-approved product was not appropriate
- The specific formulation and dose requested
A weak file is one of the fastest ways a compounding arrangement can fall outside the exemption.
Checklist: What a Valid Compounded GLP-1 Prescription Should Contain
Use this checklist to review a prescription before filling it. It is a practical screen, not a legal opinion, and a licensed pharmacist should confirm details. (Source: FDA clarification on compounding exemptions under sections 503A and 503B)

- Patient’s full name and date of birth
- Prescriber’s name, license number, and contact information
- Drug name, strength, and dosage form
Patients should also confirm that the pharmacy is licensed in their state and works with the prescriber.
The checklist below lists the elements a prescription should include before it is filled.
| Element | What to check | Note |
|---|---|---|
| Patient identity | Full name and date of birth | Must match the patient |
| Prescriber | Name, license number, contact | Must be a licensed prescriber |
| Drug details | Name, strength, dosage form | Specific to the product |
| Dose and directions | Dose and how to use | Written out clearly |
| Quantity | Amount and refills | Stated on the prescription |
| Date | Date of prescription | Must be present |
| Clinical reason | Documented need for compounded product | Required for the exemption |
| Signature | Licensed prescriber’s signature | Required before filling |
Checking Whether Compounded GLP-1 Is Still Permitted: Shortage Status and Ban Updates
Shortage status is the single most changeable factor in whether a compounded GLP-1 product may be made under the shortage exemption. The rules are not static, and a prescription that was fillable last month may not be fillable today. This section gives a practical way to confirm status before prescribing or dispensing.
How shortage status affects compounding eligibility
FDA maintains a drug shortage database that lists products in shortage and products that have been resolved.
FDA has used transition periods to give compounders and prescribers time to adjust after a shortage resolution. The length and terms of those periods are announced by FDA and can change, so the only reliable source is FDA’s current announcement and the current shortage database entry.
Step-by-step: confirming current status before you prescribe or fill
- Check the FDA drug shortage database entry for the specific product and strength. Status can differ by dosage form and strength, so confirm the exact product, not just the active ingredient.
- Read any FDA statement about resolution or transition for that product. Look for the effective date and any enforcement discretion period.
- Confirm the state board of pharmacy position. Some states impose additional limits on compounding copies of approved products even when a federal shortage exists.
- Confirm the pharmacy’s own policy. A pharmacy may stop compounding a product earlier than the federal deadline.
- Document the status check in the patient record. Record the date checked, the source, and the result.
- Recheck at each refill. A past check does not guarantee future eligibility.
Watch out: relying on a pharmacy’s marketing page or a social media post for shortage status is a common way to fill a prescription that is no longer permitted; confirm against the FDA database and the state board directly.
What changes when a shortage resolves
When FDA removes a product from the shortage list, the practical effects for a patient and prescriber are usually:
- The shortage exemption for copying the approved product narrows or ends, subject to any transition period.
- Prescribers may need to document a different clinical justification, such as a documented clinically significant difference, if compounding is to continue.
- Pharmacies may need to stop dispensing the compounded version and help transition the patient to an FDA-approved product.
A common pattern is for patients to learn about a shortage resolution only when their refill is refused. Asking the prescriber and pharmacist to confirm status at each visit avoids that surprise.
How to confirm the latest status
The authoritative sources are the FDA drug shortage database, FDA statements on compounding and shortage resolution, and the relevant state board of pharmacy. Confirm all three before starting or continuing a compounded GLP-1 prescription, and keep a dated record of what was checked.
Safety Considerations for Compounded Semaglutide and Compounded B12 Blends
Compounded products do not go through the same review as approved drugs.
Compounded blends that add vitamin B12 should be understood as having an added ingredient that needs its own clinical reason and monitoring.
Side effects such as nausea can occur with any GLP-1 medication. Tell your prescriber about any reaction early.
For more on long-term safety, see our guide to long-term effects of compounded semaglutide and our review of compounded tirzepatide safety.
Next Step: Confirming Eligibility and Verifying Your Prescriber and Pharmacy
Before you start, confirm three things: that your prescriber is licensed in your state, that the pharmacy is licensed and accredited, and that your prescription meets the requirements above. Ask for written answers.
If you are comparing providers, read about choosing a telehealth provider for compounded semaglutide and finding a reputable compounding pharmacy.
A consultation with a licensed clinician can review your history and discuss whether a compounded option is appropriate for you. Bring your current medication list and any prior prescriptions to that visit.
Frequently Asked Questions
Do I need a prescription for compounded GLP-1?
Yes. Under federal rules for compounding pharmacies, a compounded GLP-1 generally must be prescribed for an individual patient based on a valid prescription from a licensed prescriber. The FDA states that compounding under section 503A is tied to the receipt of a prescription for an identified patient. Pharmacies that dispense without a patient-specific prescription may fall outside the exemptions that permit compounding. Ask any provider to explain how your prescription was issued and what clinical evaluation supported it before you begin treatment.
What qualifies you for a GLP-1 prescription?
Eligibility depends on the prescriber’s clinical evaluation of your health history, weight, and medical need, along with any conditions such as pre-diabetes or hypothyroidism. General information cannot determine whether you qualify. A consultation with a licensed clinician who can review your medical records and medications is the appropriate way to find out. Bring a list of current medications, prior weight-management attempts, and any relevant lab results to that visit.
Is compounded GLP-1 still legal?
Compounded GLP-1 medications are permitted only under specific conditions, such as individual-patient prescriptions and periods when the drug is not on the FDA shortage list. FDA shortage status has changed over time, so the legal picture can shift. Check the current FDA drug shortage database and your state board of pharmacy before relying on any compounded product. Your prescriber or pharmacist should be able to confirm the basis on which the medication is being supplied.
How can I check whether a compounded GLP-1 pharmacy is legitimate?
Confirm that the pharmacy is licensed by your state board of pharmacy, and check whether a compounding facility is registered with the FDA if it operates as an outsourcing facility. Verify the prescriber’s license through your state medical board. Accreditation from a recognized body is a voluntary quality signal rather than a legal requirement, so treat it as additional evidence. Ask how the pharmacy sources its bulk drug substances and how it handles quality control and documentation.